Home › Companies › Mirum Pharmaceuticals, Inc. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Mirum Pharmaceuticals, Inc.’s Form 8-K, filed May 30, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 29, 2025: 5 items on Mirum Pharmaceuticals, Inc.’s Form 8-K, filed May 30, 2025: 2 approved · 2 passed (calculated) · 1 plurality election.
Significant dissent: 1 director (50.3% against).
Notable dissent: 1 director (14.8% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Tang Capital (13F, 1.9%, as of September 30, 2026)
Explore Mirum Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Mirum Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 30, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Laura Brege | 17,968,766 | -- | -- | 18,167,097 | 7,017,835 | 49.7% | Plurality election | — |
| Elect Director: Michael Grey | 30,777,470 | -- | -- | 5,358,393 | 7,017,835 | 85% | Passed (calculated) | — |
| Elect Director: Christopher Peetz | 35,980,278 | -- | -- | 155,585 | 7,017,835 | 99.6% | Passed (calculated) | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm | 43,115,134 | 19,188 | 19,376 | -- | -- | 99.9% | Approved | — |
| 3. Advisory Vote on Executive Compensation | 34,671,826 | 1,455,143 | 8,894 | -- | 7,017,835 | 96% | Approved | — |
Source: Mirum Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 30, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
248 asset managers disclosed a vote on at least one Mirum Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Christopher Peetz
Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Christopher Peetz”): 35,980,278 for, 155,585 withheld, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 2,516,344 | 0 | 0 | 0 | For |
| Vanguard | 2,491,637 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,880,346 | 0 | 0 | 0 | For |
| BlackRock | 1,084,414 | 0 | 0 | 0 | For |
| T. Rowe Price | 982,103 | 0 | 0 | 0 | For |
| Legg Mason | 794,740 | 0 | 0 | 0 | For |
| Fidelity | 776,976 | 0 | 0 | 0 | For |
| TIAA | 628,349 | 0 | 0 | 0 | For |
| State Street | 521,162 | 0 | 0 | 0 | For |
| Lord Abbett | 379,282 | 0 | 0 | 0 | For |
| Loomis Sayles | 329,204 | 0 | 0 | 0 | For |
| Charles Schwab | 327,690 | 0 | 0 | 0 | For |
| Federated Hermes | 327,010 | 0 | 0 | 0 | For |
| Invesco | 284,600 | 0 | 0 | 0 | For |
| Waddell & Reed | 247,779 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 215,190 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 157,331 | 0 | 0 | 0 | For |
| Equitable | 149,393 | 0 | 0 | 0 | For |
| First Trust | 128,774 | 0 | 0 | 0 | For |
| Brighthouse | 106,834 | 0 | 0 | 0 | For |
| Russell Investments | 94,313 | 0 | 0 | 0 | For |
| JPMorgan | 89,172 | 0 | 0 | 0 | For |
| Calamos | 85,593 | 0 | 0 | 0 | For |
| BNY Mellon | 82,426 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 67,687 | 0 | 0 | 0 | For |
Fund voting reports, all 73 managers: 15,396,904 for, 3,228 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 0 | 0 | 0 | 260,000 | Withhold |
| BOSUN ASSET MANAGEMENT, LLC | 3,490 | 0 | 0 | 0 | For |
| RWC Asset Management LLP | 2,807 | 0 | 0 | 0 | For |
Institutional-manager reports, all 3 managers: 6,297 for, 260,000 withheld.
Combines 4 wordings of this item as funds reported it.
49.7% Plurality election · of votes cast
Description as filed by funds: To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Laura Brege
Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Laura Brege”): 17,968,766 for, 18,167,097 withheld, per its Form 8-K filed May 30, 2025 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.
Outcome: Plurality election — The company’s filing reports the vote counts but does not state the outcome; this is an election decided by plurality, so a nominee does not need a majority of the votes cast and no passed or failed outcome is calculated.
Support: 49.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 2,516,344 | 0 | 0 | 0 | For |
| Vanguard | 2,459,937 | 0 | 0 | 31,700 | For |
| JANUS INVESTMENT FUND | 0 | 0 | 0 | 1,880,346 | Withhold |
| BlackRock | 11,375 | 0 | 0 | 1,073,039 | Withhold |
| T. Rowe Price | 982,103 | 0 | 0 | 0 | For |
| Legg Mason | 792,193 | 0 | 0 | 2,547 | For |
| Fidelity | 738,035 | 0 | 0 | 38,941 | Mixed |
| TIAA | 628,349 | 0 | 0 | 0 | For |
| State Street | 1,274 | 0 | 0 | 519,888 | Withhold |
| Lord Abbett | 0 | 0 | 0 | 379,282 | Withhold |
| Loomis Sayles | 0 | 0 | 0 | 329,204 | Withhold |
| Charles Schwab | 327,690 | 0 | 0 | 0 | For |
| Federated Hermes | 327,010 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 284,600 | Withhold |
| Waddell & Reed | 0 | 0 | 0 | 247,779 | Withhold |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 215,190 | Withhold |
| Columbia Threadneedle | 0 | 0 | 0 | 157,331 | Withhold |
| Equitable | 0 | 0 | 0 | 149,393 | Withhold |
| First Trust | 0 | 0 | 0 | 128,774 | Withhold |
| Brighthouse | 33,180 | 0 | 0 | 73,654 | Mixed |
| Russell Investments | 0 | 0 | 0 | 94,313 | Withhold |
| JPMorgan | 89,172 | 0 | 0 | 0 | For |
| Calamos | 85,593 | 0 | 0 | 0 | For |
| BNY Mellon | 82,426 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 67,687 | Withhold |
Fund voting reports, all 73 managers: 9,217,505 for, 6,182,627 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 260,000 | 0 | 0 | 0 | For |
| BOSUN ASSET MANAGEMENT, LLC | 3,490 | 0 | 0 | 0 | For |
| RWC Asset Management LLP | 2,807 | 0 | 0 | 0 | For |
Institutional-manager reports, all 3 managers: 266,297 for.
Combines 4 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Michael Grey
Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Michael Grey”): 30,777,470 for, 5,358,393 withheld, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 2,516,344 | 0 | 0 | 0 | For |
| Vanguard | 2,491,637 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,880,346 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 1,084,414 | Withhold |
| T. Rowe Price | 982,103 | 0 | 0 | 0 | For |
| Legg Mason | 794,740 | 0 | 0 | 0 | For |
| Fidelity | 760,735 | 0 | 0 | 16,241 | For |
| TIAA | 628,349 | 0 | 0 | 0 | For |
| State Street | 1,862 | 0 | 0 | 519,300 | Withhold |
| Lord Abbett | 379,282 | 0 | 0 | 0 | For |
| Loomis Sayles | 329,204 | 0 | 0 | 0 | For |
| Charles Schwab | 327,690 | 0 | 0 | 0 | For |
| Federated Hermes | 327,010 | 0 | 0 | 0 | For |
| Invesco | 284,600 | 0 | 0 | 0 | For |
| Waddell & Reed | 0 | 0 | 0 | 247,779 | Withhold |
| FRANKLIN STRATEGIC SERIES | 215,190 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 157,331 | 0 | 0 | 0 | For |
| Equitable | 36,883 | 0 | 0 | 112,510 | Mixed |
| First Trust | 128,774 | 0 | 0 | 0 | For |
| Brighthouse | 106,834 | 0 | 0 | 0 | For |
| Russell Investments | 94,313 | 0 | 0 | 0 | For |
| JPMorgan | 89,172 | 0 | 0 | 0 | For |
| Calamos | 85,593 | 0 | 0 | 0 | For |
| BNY Mellon | 82,426 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 67,687 | Withhold |
Fund voting reports, all 73 managers: 13,170,405 for, 2,229,727 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 260,000 | 0 | 0 | 0 | For |
| BOSUN ASSET MANAGEMENT, LLC | 3,490 | 0 | 0 | 0 | For |
| RWC Asset Management LLP | 2,807 | 0 | 0 | 0 | For |
Institutional-manager reports, all 3 managers: 266,297 for.
Combines 9 wordings of this item as funds reported it.
96% Approved · of votes cast
Prior year: 96.7% for (June 5, 2024 meeting) ▼ 0.7 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.
Mirum Pharmaceuticals, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 34,671,826 for, 1,455,143 against — passed, per its Form 8-K filed May 30, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement for the Annual Meeting.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 2,516,344 | 0 | 0 | 0 | For |
| Vanguard | 2,491,637 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,880,346 | 0 | 0 | 0 | For |
| BlackRock | 1,084,414 | 0 | 0 | 0 | For |
| T. Rowe Price | 982,103 | 0 | 0 | 0 | For |
| Legg Mason | 794,740 | 0 | 0 | 0 | For |
| Fidelity | 776,976 | 0 | 0 | 0 | For |
| TIAA | 628,349 | 0 | 0 | 0 | For |
| State Street | 521,162 | 0 | 0 | 0 | For |
| Lord Abbett | 379,282 | 0 | 0 | 0 | For |
| Loomis Sayles | 329,204 | 0 | 0 | 0 | For |
| Charles Schwab | 327,690 | 0 | 0 | 0 | For |
| Federated Hermes | 327,010 | 0 | 0 | 0 | For |
| Invesco | 284,600 | 0 | 0 | 0 | For |
| Waddell & Reed | 247,779 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 215,190 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 157,331 | 0 | 0 | Against |
| Equitable | 149,393 | 0 | 0 | 0 | For |
| First Trust | 128,774 | 0 | 0 | 0 | For |
| Brighthouse | 106,834 | 0 | 0 | 0 | For |
| Russell Investments | 94,313 | 0 | 0 | 0 | For |
| JPMorgan | 89,172 | 0 | 0 | 0 | For |
| Calamos | 85,593 | 0 | 0 | 0 | For |
| BNY Mellon | 0 | 82,426 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 67,687 | 0 | 0 | 0 | For |
Fund voting reports, all 74 managers: 15,162,260 for, 254,500 against, 3,228 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 4,677,659 | 0 | 0 | 0 | For |
| BVF INC/IL | 2,761,333 | 0 | 0 | 0 | For |
| Novo Holdings A/S | 1,500,000 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,349,869 | 0 | 0 | 0 | For |
| State Street | 1,301,060 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 968,546 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 951,765 | 0 | 0 | 0 | For |
| BlackRock | 907,379 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 732,335 | 0 | 0 | 0 | For |
| Citadel | 727,381 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 704,954 | 0 | 0 | 0 | For |
| Nuveen | 654,722 | 0 | 0 | 0 | For |
| BOONE CAPITAL MANAGEMENT LLC | 603,318 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 592,514 | 0 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 588,552 | 0 | 0 | 0 | For |
| Loomis Sayles | 555,379 | 0 | 0 | 0 | For |
| Point72 | 447,361 | 0 | 0 | 0 | For |
| DE Shaw | 396,415 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 369,198 | 0 | 0 | Against |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 357,828 | 0 | 0 | 0 | For |
| AXA INVESTMENT MANAGERS UK Ltd | 0 | 351,372 | 0 | 0 | Against |
| Federated Hermes | 336,050 | 0 | 0 | 0 | For |
| Charles Schwab | 327,696 | 0 | 0 | 0 | For |
| Invesco | 303,187 | 0 | 0 | 0 | For |
| UniSuper Management Pty Ltd | 274,141 | 0 | 0 | 0 | For |
Institutional-manager reports, all 197 managers: 25,427,233 for, 1,115,502 against, 7,822 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 99.9% for (June 5, 2024 meeting) ▲ 0.1 pts
Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.
Mirum Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 43,115,134 for, 19,188 against — passed, per its Form 8-K filed May 30, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending …”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Mirum Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, 21,025 for).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 2,516,344 | 0 | 0 | 0 | For |
| Vanguard | 2,491,637 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,880,346 | 0 | 0 | 0 | For |
| BlackRock | 1,084,414 | 0 | 0 | 0 | For |
| T. Rowe Price | 982,103 | 0 | 0 | 0 | For |
| Legg Mason | 794,740 | 0 | 0 | 0 | For |
| Fidelity | 776,976 | 0 | 0 | 0 | For |
| TIAA | 628,349 | 0 | 0 | 0 | For |
| State Street | 521,162 | 0 | 0 | 0 | For |
| Lord Abbett | 379,282 | 0 | 0 | 0 | For |
| Loomis Sayles | 329,204 | 0 | 0 | 0 | For |
| Charles Schwab | 327,690 | 0 | 0 | 0 | For |
| Federated Hermes | 327,010 | 0 | 0 | 0 | For |
| Invesco | 284,600 | 0 | 0 | 0 | For |
| Waddell & Reed | 247,779 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 215,190 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 157,331 | 0 | 0 | 0 | For |
| Equitable | 149,393 | 0 | 0 | 0 | For |
| First Trust | 128,774 | 0 | 0 | 0 | For |
| Brighthouse | 106,834 | 0 | 0 | 0 | For |
| Russell Investments | 94,313 | 0 | 0 | 0 | For |
| JPMorgan | 89,172 | 0 | 0 | 0 | For |
| Calamos | 85,593 | 0 | 0 | 0 | For |
| BNY Mellon | 82,426 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 67,687 | 0 | 0 | 0 | For |
Fund voting reports, all 72 managers: 15,395,735 for, 3,228 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 260,000 | 0 | 0 | 0 | For |
| BOSUN ASSET MANAGEMENT, LLC | 3,490 | 0 | 0 | 0 | For |
| RWC Asset Management LLP | 2,807 | 0 | 0 | 0 | For |
Institutional-manager reports, all 3 managers: 266,297 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 49,451,223 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | MUTUAL FUND SERIES TRUST | 5.09% |
| 2 | Vanguard | 5.04% |
| 3 | JANUS INVESTMENT FUND | 3.80% |
| 4 | BlackRock | 2.19% |
| 5 | T. Rowe Price | 1.99% |
| 6 | Legg Mason | 1.61% |
| 7 | Fidelity | 1.57% |
| 8 | TIAA | 1.27% |
| 9 | State Street | 1.05% |
| 10 | Lord Abbett | 0.77% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 9.46% |
| 2 | BVF INC/IL | 5.58% |
| 3 | Novo Holdings A/S | 3.03% |
| 4 | T. Rowe Price | 2.73% |
| 5 | State Street | 2.63% |
| 6 | Clearbridge Investments, LLC | 1.96% |
| 7 | Rock Springs Capital Management LP | 1.92% |
| 8 | BlackRock | 1.83% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.48% |
| 10 | Citadel | 1.47% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 6,065,308 | 12.27% | Schedule 13G, filed February 17, 2026 |
| James N. Topper | 4,025,922 | 8.14% | Schedule 13D, filed January 27, 2026 |
| Patrick Heron | 3,797,220 | 7.68% | Proxy statement (DEF 14A), table as of February 15, 2025 |
| Frazier Life Sciences IX, L.P. | 3,566,912 | 7.21% | Schedule 13D, filed November 4, 2025 |
| BlackRock | 3,339,557 | 6.75% | Form 13F, quarter ended March 31, 2025 |
| Biotechnology Value Fund, L.P. | 3,075,907 | 6.22% | Proxy statement (DEF 14A), table as of February 15, 2025 |
| Vanguard Group | 2,540,061 | 5.14% | Form 13F, quarter ended March 31, 2025 |
| Eventide Asset Management, LLC | 2,093,582 | 4.23% | Schedule 13G, filed February 13, 2026 |
| Christopher Peetz | 1,717,976 | 3.47% | Proxy statement (DEF 14A), table as of February 15, 2025 |
| BVF PARTNERS L P/IL | 1,495,290 | 3.02% | Schedule 13G, filed November 14, 2025 |
Percentages above are of 49,451,223 shares outstanding, as reported by Mirum Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Mirum Pharmaceuticals, Inc.'s shareholder meeting held May 29, 2025, in the 2024-2025 proxy season, 248 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,327 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — Mirum Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Mirum Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 30, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Mirum Pharmaceuticals, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Mirum Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “Mirum Pharmaceuticals (MIRM) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/mirum-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.